GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (NAS:GLPG) » Definitions » Cyclically Adjusted Revenue per Share

Galapagos NV (Galapagos NV) Cyclically Adjusted Revenue per Share : $6.10 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Galapagos NV Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Galapagos NV's adjusted revenue per share for the three months ended in Mar. 2024 was $1.030. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $6.10 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Galapagos NV's average Cyclically Adjusted Revenue Growth Rate was -0.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 1.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Galapagos NV was 1.20% per year. The lowest was 1.20% per year. And the median was 1.20% per year.

As of today (2024-06-06), Galapagos NV's current stock price is $27.16. Galapagos NV's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $6.10. Galapagos NV's Cyclically Adjusted PS Ratio of today is 4.45.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Galapagos NV was 35.11. The lowest was 4.51. And the median was 8.30.


Galapagos NV Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Galapagos NV's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Cyclically Adjusted Revenue per Share Chart

Galapagos NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 6.58 6.04 6.11 6.10

Galapagos NV Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.15 6.42 6.36 6.10 6.10

Competitive Comparison of Galapagos NV's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Galapagos NV's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galapagos NV's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galapagos NV's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Galapagos NV's Cyclically Adjusted PS Ratio falls into.



Galapagos NV Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Galapagos NV's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.03/130.5518*130.5518
=1.030

Current CPI (Mar. 2024) = 130.5518.

Galapagos NV Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 99.482 0.000
201409 0.572 99.195 0.753
201412 0.838 99.086 1.104
201503 0.528 99.423 0.693
201506 0.387 100.107 0.505
201509 0.164 100.245 0.214
201512 0.201 100.572 0.261
201603 0.248 101.653 0.319
201606 0.671 102.267 0.857
201609 0.264 102.118 0.338
201612 1.815 102.614 2.309
201703 0.786 103.972 0.987
201706 0.603 103.902 0.758
201709 0.640 104.170 0.802
201712 0.915 104.804 1.140
201803 0.915 105.419 1.133
201806 1.119 106.063 1.377
201809 2.089 106.618 2.558
201812 2.019 107.252 2.458
201903 0.683 107.876 0.827
201906 1.208 107.896 1.462
201909 11.654 107.470 14.157
201912 1.810 108.065 2.187
202003 1.538 108.550 1.850
202006 1.725 108.540 2.075
202009 2.292 108.441 2.759
202012 2.906 108.511 3.496
202103 2.028 109.522 2.417
202106 2.570 110.305 3.042
202109 1.152 111.543 1.348
202112 -1.442 114.705 -1.641
202203 2.256 118.620 2.483
202206 2.213 120.948 2.389
202209 2.048 124.120 2.154
202212 -2.953 126.578 -3.046
202303 0.946 126.528 0.976
202306 4.480 125.973 4.643
202309 1.929 127.083 1.982
202312 -3.483 128.292 -3.544
202403 1.030 130.552 1.030

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Galapagos NV  (NAS:GLPG) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Galapagos NV's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=27.16/6.1
=4.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Galapagos NV was 35.11. The lowest was 4.51. And the median was 8.30.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Galapagos NV Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Galapagos NV (Galapagos NV) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (NAS:GLPG) » Definitions » Cyclically Adjusted Revenue per Share
Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.